A new study has found that individuals that have previously contracted COVID-19 show a more potent antibody response than those who were solely vaccinated for the respiratory virus.<\/p>\n
Conducted by a research team at Rockefeller University in New York, the analysis found that between a first (prime) and second (booster) shot of either the Pfizer-BioNTech or Moderna vaccine, the memory B cells of infection-nave individuals produced antibodies that evolved increased neutralizing activity against SARS-CoV-2, but also that no additional increase in the potency or breadth of this activity was observed thereafter.<\/p>\n
Meanwhile, researchers determined that not only do recovered COVID-19 patients possess neutralizing antibodies up to a year after infection, but that such infection simultaneously assists in offering protection against developing variants.<\/p>\n
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B-cell responses that continue to evolve for at least one year, the study read. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to mutations found in variants of concern.<\/p>\n
The analysis later goes on to conclude, Memory antibodies selected over time by natural infection have greater potency and breadth than antibodies elicited by vaccination.<\/p>\n
Moreover, the results suggest that boosting vaccinated individuals with currently available mRNA vaccines would produce a quantitative increase in plasma neutralizing activity but not the qualitative advantage against variants obtained by vaccinating convalescent individuals.<\/p>\n
The studys findings add to further mounting evidence detailing the level of protection natural immunity offers previously infected COVID-19 patients. Last month, Emory University published an extensive investigation describing the efficiency of long-term immunity against the respiratory virus. Similar discoveries have also been identified in research released by the Cleveland Clinic and the Washington University School of Medicine in St. Louis, respectively.<\/p>\n
Shawn Fleetwood is an intern at The Federalist and a student at the University of Mary Washington, where he plans to major in Political Science and minor in Journalism. He also serves as a state content writer for Convention of States Action. Follow him on Twitter @ShawnFleetwood<\/p>\n
<\/p>\n
More here: <\/p>\n
Study Finds Greater Antibody Response In Recovered COVID-19 Patients Than Vaccinated Ones - The Federalist<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" A new study has found that individuals that have previously contracted COVID-19 show a more potent antibody response than those who were solely vaccinated for the respiratory virus. Conducted by a research team at Rockefeller University in New York, the analysis found that between a first (prime) and second (booster) shot of either the Pfizer-BioNTech or Moderna vaccine, the memory B cells of infection-nave individuals produced antibodies that evolved increased neutralizing activity against SARS-CoV-2, but also that no additional increase in the potency or breadth of this activity was observed thereafter. Continue reading